| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | L9; ENH; LIM; ENH1 |
| WB Predicted band size | 64 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human PDLIM5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与PDLIM5抗体相关的文献摘要概述，供参考：
---
1. **"PDLIM5 regulates cell proliferation and motility in cancer cells through NF-κB signaling"**
*作者：Yamada R, et al.*
摘要：研究利用PDLIM5特异性抗体，发现其在多种癌细胞系中通过调控NF-κB通路影响细胞增殖和迁移，提示其作为癌症治疗潜在靶点。
2. **"Altered PDLIM5 expression in bipolar disorder patients: A postmortem brain study"**
*作者：Hori H, et al.*
摘要：通过免疫组化和Western blot结合PDLIM5抗体，发现双相情感障碍患者前额叶皮层中PDLIM5蛋白表达显著降低，可能与神经突触功能异常相关。
3. **"PDLIM5 interacts with α-actinin in cardiomyocytes to modulate sarcomere organization"**
*作者：Chen L, et al.*
摘要：使用PDLIM5抗体进行共聚焦显微镜和免疫共沉淀实验，揭示其在心肌细胞中与α-辅肌动蛋白互作，调节肌节结构和心脏收缩功能。
---
注：以上为示例性内容，实际文献需通过PubMed/Google Scholar检索确认。建议使用关键词“PDLIM5 antibody Western blot”或“PDLIM5 immunohistochemistry”查找实验方法学相关论文。
**Background of PDLIM5 Antibody**
PDLIM5 (PDZ and LIM domain protein 5), also known as LIMK1-binding protein or ENH2. is a cytoskeletal protein belonging to the ALP/Enigma family. It contains a PDZ domain at the N-terminus and three LIM domains at the C-terminus, enabling interactions with various signaling molecules, kinases, and structural proteins. PDLIM5 is implicated in regulating cell adhesion, cytoskeletal organization, and intracellular signaling pathways, particularly those involving actin dynamics. It also plays roles in neuronal development, cardiac function, and cancer progression.
Antibodies targeting PDLIM5 are essential tools for studying its expression, localization, and function in biological systems. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect PDLIM5 in tissues or cultured cells. Research utilizing these antibodies has linked PDLIM5 dysregulation to neuropsychiatric disorders (e.g., schizophrenia), cardiovascular diseases, and tumor metastasis, highlighting its potential as a therapeutic or diagnostic marker.
Commercial PDLIM5 antibodies are typically raised in hosts like rabbits or mice, with validation in specific applications. Researchers must verify antibody specificity using knockout controls or peptide blocking assays due to possible cross-reactivity with homologous LIM-domain proteins. Recent studies continue to explore PDLIM5's role in mechanotransduction and disease mechanisms, driving demand for reliable antibodies in experimental and clinical contexts.
×
